AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32791721
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (3 ml supernatant of maternal vaginal bacteria)
Trial: 32791721
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 ml sterile water)
Trial: 32791721
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (3 ml supernatant)
Trial: 32918971
Drug: Single 19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 19 Gy HDR implant to the whole prostate (Trial1)
Trial: 32184185
Drug: Minesapride 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minesapride 12 mg
Trial: 36498963
Drug: Methylone 50
RxNorm normalized name: Methylone
DrugBank: Methylone (DB19192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylone 50 mg
Trial: 36498963
Drug: Methylone 100
RxNorm normalized name: Methylone
DrugBank: Methylone (DB19192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylone 100 mg
Trial: 36498963
Drug: Methylone 150
RxNorm normalized name: Methylone
DrugBank: Methylone (DB19192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylone 150 mg
Trial: 36498963
Drug: Methylone 200
RxNorm normalized name: Methylone
DrugBank: Methylone (DB19192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylone 200 mg
Trial: 33166056
Drug: CYP2D6 poor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2D6 poor and intermediate metabolizers after the eighth week of treatment
Trial: 39094677
Drug: Methylprednisolone 250
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 250 mg
Trial: 33982068
Drug: 5 μg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg of ramosetron (Irribow®) daily for 4 weeks
Trial: 33982068
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment for 4 weeks
Trial: 33289844
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 supplementation (2800 IU/d)
Trial: 33289844
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose vitamin D3 supplementation (400 IU/d)
Trial: 34315522
Drug: Modified resistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified resistant starch (40 g/day)
Trial: 32091560
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative therapy (OMTh), 4 sessions over 2 months
Trial: 32079916
Drug: Leucine supplementation
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine supplementation (2 × 5 g·d)
Trial: 32079916
Drug: Alanine supplementation
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alanine supplementation (2 × 5 g·d)
Trial: 33744812
Drug: abiraterone/prednisone combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abiraterone/prednisone combination
Trial: 33744812
Drug: enzalutamide combination
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: enzalutamide combination
Trial: 33744812
Drug: radium-223 monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radium-223 monotherapy
Trial: 32442298
Drug: Fixed-dose enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose enoxaparin (40 mg daily)
Trial: 32442298
Drug: Weight-adjusted enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-adjusted enoxaparin (1 mg/kg daily)
Trial: 33618657
Drug: Last kilometre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Last kilometre medicine delivery service
Trial: 33618657
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application for ordering medicines
Trial: 33618657
Drug: Home delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home delivery of medicines
Trial: 32797125
Drug: Ubiquinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol (200 mg day‐1)
Trial: 36440058
Drug: Moringa oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa oleifera capsules
Trial: 32105267
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 mg once a day at night for 3 months)
Trial: 32323103
Drug: AE37 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AE37 vaccine (VG)
Trial: 32323103
Drug: GP2 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP2 vaccine (VG)
Trial: 35057577
Drug: Calanus oil
RxNorm normalized name: CALANUS OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calanus oil (2 g CO/day)
Trial: 35057577
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 g paraffin oil/day)
Trial: 33278899
Drug: Micronutrient Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient Powder Supplementation (MNP) alongside National Micronutrient Supplement (NMS) - 3 sachets/week for 12 months
Trial: 33583158
Drug: Artemisia supplementation
RxNorm normalized name: Artemisia vulgaris top oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisia supplementation (250 mg/day for six weeks)
Trial: 33583158
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mg/day for six weeks)
Trial: 32358413
Drug: Romosozumab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romosozumab (various doses)
Trial: 34969035
Drug: Hedan tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hedan tablets at 4.38 g/day tid
Trial: 33461965
Drug: green-MED diet
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: green-MED diet (100 g/day Mankai, 3-4 cups/day green tea, 28 g/day walnuts)
Trial: 33461965
Drug: MED diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MED diet (28 g/day walnuts)
Trial: 35767123
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) treatment
Trial: 32116098
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin treatment
Trial: 34531823
Drug: Cannabis treatment
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis treatment for 8 weeks
Trial: 32028411
Drug: OPEA+SPOA (preemptive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPEA+SPOA (preemptive oxycodone and postoperative sufentanil)
Trial: 33624330
Drug: Anodic tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodic tDCS (A-tDCS) 2 mA for 20 min concurrent with speech language therapy (SLT)
Trial: 33624330
Drug: Sham tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham tDCS (S-tDCS) current started at 2 mA but decreased to 0 mA after 30 sec, concurrent with speech language therapy (SLT)
Trial: 32865434
Drug: Intra-operative wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative wound irrigation with ceftriaxone in normal saline solution
Trial: 33524876
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma transfusion and standard therapy (n = 9)
Trial: 33524876
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy alone (n = 9)
Trial: 35855382
Drug: Virtual painting
RxNorm normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Virtual painting therapy directed by WhatsApp (six 2-hour group sessions once a week for six weeks)
Trial: 32973199
Drug: 2 mg/ml
RxNorm normalized name: urea 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/ml phenazine application
Trial: 32973199
Drug: 0.048 mg/ml
RxNorm normalized name: ipecac 0.048 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.048 mg/ml hexaconazole application
Trial: 32973199
Drug: 1 mg/ml
RxNorm normalized name: urea 1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/ml phenazine application
Trial: 32973199
Drug: G. boninense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. boninense inoculated seedlings
Trial: 32470574
Drug: New generic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New generic S-1 (50 mg)
Trial: 32470574
Drug: Original brand-name
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original brand-name S-1 (50 mg)
Trial: 34105089
Drug: Prototype mini
RxNorm normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype mini lozenge (2 or 4 mg dose)
Trial: 34105089
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available mini lozenge
Trial: 34105089
Drug: Prototype mini
RxNorm normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype mini lozenge
Trial: 32067098
Drug: Polyphenol-rich (PR)
RxNorm normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol-rich (PR) supplements (4.8 g/day for 4 months)
Trial: 32067098
Drug: Polyphenols-free (PF)
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenols-free (PF) supplements (4.8 g/day for 4 months)
Trial: 33901452
Drug: Double Thread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Thread Suspension (DTS)
Trial: 34526071
Drug: Individually tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually tailored diet and oral health advice
Trial: 32608554
Drug: MNS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNS treatment group (N = 30)
Trial: 35592818
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) group received 0.2% ropivacaine 4 mL/h
Trial: 35592818
Drug: PIBI1 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIBI1 group received intermittent 0.2% ropivacaine boluses at 4 mL/h
Trial: 35592818
Drug: PIBI2 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIBI2 group received intermittent 0.2% ropivacaine boluses at 8 mL/2 h
Trial: 35592818
Drug: PIBI3 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIBI3 group received intermittent 0.2% ropivacaine boluses at 12 mL/3 h
Trial: 33785415
Drug: Daily smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily smoking history
Trial: 35645222
Drug: Additional rapid-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional rapid-acting insulin administered at +0h
Trial: 35645222
Drug: Additional rapid-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional rapid-acting insulin administered at +1h
Trial: 35645222
Drug: Additional rapid-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional rapid-acting insulin administered at +2h
Trial: 33692190
Drug: Smart agent
RxNorm normalized name: benzalkonium chloride Topical Foam [Smart San]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smart agent (SA) system
Trial: 33781141
Drug: BMS‐986020 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐986020 600 mg once daily (QD)
Trial: 33781141
Drug: BMS‐986020 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐986020 600 mg twice daily (BID)
Trial: 32106642
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin (25,000 IU) and salbutamol (5 mg) every 6 hours
Trial: 32106642
Drug: Salbutamol only
RxNorm normalized name: Salbutamol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol only (5 mg)
Trial: 36471692
Drug: Remimazolam tosylate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam tosylate plus low-dose propofol (Group RP)
Trial: 34916266
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone (6 mg once daily for 10 days)
Trial: 34916266
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for an additional 5 days)
Trial: 32019723
Drug: MLR-1023 100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLR-1023 100-mg once-daily (qd)
Trial: 32019723
Drug: MLR-1023 100-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLR-1023 100-mg twice-daily (bid)
Trial: 32019723
Drug: MLR-1023 200-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLR-1023 200-mg once-daily (qd)
Trial: 32019723
Drug: MLR-1023 200-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLR-1023 200-mg twice-daily (bid)
Trial: 32931400
Drug: Olanzapine 0.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 0.14 mg/kg/day (maximum 10 mg) during chemotherapy and 3 days postchemotherapy
Trial: 33508499
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS treatment (5-Hz) for 2 weeks
Trial: 33508499
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS treatment (5-Hz) for 6 months (open-label maintenance phase)
Trial: 33508499
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment for 2 weeks
Trial: 36153583
Drug: Atorvastatin (n=27)
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (n=27)
Trial: 35638203
Drug: Three PRP
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three PRP injections
Trial: 35638203
Drug: One PRP
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One PRP injection followed by two placebo injections
Trial: 35638203
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections (Normal Saline)
Trial: 35638203
Drug: Single or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple PRP injections
Trial: 35638203
Drug: Single PRP
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single PRP injection
Trial: 35638203
Drug: Multiple PRP
RxNorm normalized name: HEMOPHILUS B PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple PRP injections
Trial: 32856285
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil (0.5 mg/kg every 6 hours to a target maintenance dose of 2 mg/kg every 6 hours)
Trial: 32856285
Drug: Intravenous milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous milrinone (0.5 μg/kg/min as a continuous infusion)
Trial: 32856285
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil and intravenous milrinone (dual therapy)
Trial: 35360742
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of TEAS and palonosetron
Trial: 35164840
Drug: Intranasal dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal dexamethasone
Trial: 35164840
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (intranasal and intravenous dexamethasone)
Trial: 32591274
Drug: L-PRF membranes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRF membranes
Trial: 32366244
Drug: Lanreotide autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide autogel 60/90/120 mg (monthly deep subcutaneous injection)
Trial: 32366244
Drug: Lanreotide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 40 mg PR (intramuscular injection every 7, 10, or 14 days)
Trial: 32366244
Drug: Lanreotide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide 40 mg PR
Trial: 32452085
Drug: Patiromer (8.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer (8.4 g once daily)
Trial: 34428179
Drug: Fractionated laser
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated laser resurfacing (FLR) treatment on one lower arm
Trial: 33905494
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline 200 mg twice daily for 10 days and prednisolone 60 mg once daily for 5 days, then tapered over 5 days
Trial: 33905494
Drug: Oral doxycycline
RxNorm normalized name: doxycycline Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxycycline (historical control)
Trial: 32348882
Drug: Glucose syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose syrup (0.5-3 mL)
Trial: 32348882
Drug: Glucose syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose syrup
Trial: 33720089
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy with oral nucleoside analogue (entecavir or lamivudine) combined with subcutaneous peginterferon alfa-2a from week 8 for 56 weeks
Trial: 32171765
Drug: Intrastromal injection
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRACORONAL, DENTAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrastromal injection of voriconazole
Trial: 32171765
Drug: Topical therapy
RxNorm normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical therapy alone
Trial: 35567757
Drug: Low-dose bicyclol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bicyclol (25 mg TID)
Trial: 35567757
Drug: High-dose bicyclol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bicyclol (50 mg TID)
Trial: 36247895
Drug: Group g
RxNorm normalized name: Prostaglandin group G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group g (0.08 mCi/kg/180 s) for PET imaging
Trial: 35283082
Drug: Hormonal contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonal contraception (various methods including implants, IUDs, combined pills, progestin-only pills, injectables, ring, patch)
Trial: 33517804
Drug: L-Carnitine
RxNorm normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-Carnitine
Trial: 34366380
Drug: Foslevodopa/foscarbidopa administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foslevodopa/foscarbidopa administered via abdominal SC infusion over 72 hours
Trial: 34366380
Drug: Foslevodopa/foscarbidopa infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foslevodopa/foscarbidopa infusion
Trial: 33333055
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CA19-9 with LRG1 and TIMP1
Trial: 32697889
Drug: SCThrive intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCThrive intervention (six weekly group sessions, in-person booster session, companion app usage)
Trial: 32697889
Drug: SCHealthEd intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SCHealthEd intervention (six weekly phone calls on SCD-related and general health education topics)
Trial: 35753247
Drug: 100% pure
RxNorm normalized name: 100% Pure Australian Tea Tree Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% pure oxygen inhalation (hyperoxic CHRS testing)
Trial: 32699919
Drug: ST/gracilis (ST/G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST/gracilis (ST/G) graft with femoral pin transfixation and tibial bioscrew fixation
Trial: 32699919
Drug: ST/gracilis (ST/G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST/gracilis (ST/G) graft
Trial: 34852266
Drug: Minimal fresh
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal fresh gas flow (FGF) sevoflurane anesthesia (0.5 L.min−1)
Trial: 34852266
Drug: High fresh
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fresh gas flow (FGF) sevoflurane anesthesia (2.0 L.min−1)
Trial: 33208708
Drug: Venlafaxine (VF,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (VF, 150-375 mg/d)